Roche and Biogen Idec halt ocrelizumab RA development on infection data and deaths
This article was originally published in Scrip
Executive Summary
Development of Roche and Biogen Idec's humanised anti-CD20 monoclonal antibody ocrelizumab for rheumatoid arthritis (RA) has been halted after patients in clinical trials suffered serious opportunistic infections, some of which were fatal. The drug is also in Phase II development for relapsing-remitting multiple sclerosis (RRMS) and, at present, this study is ongoing.